Abstract
Federal regulation of the traditional art of pharmacy practice compounding is an unsettled area of the law and the profession. For many years, the Food and Drug Administration (FDA) was not interested in compounding. Attempts to regulate by FDA and Congress have caused difficulty within the profession, litigation with inconsistent results, and an unsettled state of affairs. There are a number of possible resolutions.
Get full access to this article
View all access options for this article.
References
1.US v Sullivan, 332 US 639 (1948) .
2.Professionals and Patients for Customized Care v Shalala , 56 F3d 592 (5th Cir 1995) .
3.Chevron USA, Inc v NRDC
, 467 US 837, 844 (1984) .
